Forus (formerly Tandem) raised a $150 million Series C at a $3 billion valuation announced September 8, 2026, led by Bain Capital Ventures with Accel, Thrive Capital, General Catalyst, Redpoint and others. Its AI handles insurance coverage, financial assistance and pharmacy steps between a prescription and treatment; total funding now tops $300M, four months after a $160M Series B.
AI health startup Forus raises $150M at $3B value to automate drug access
Shows investors are paying up for AI that removes back-office friction in regulated workflows; healthtech founders can frame automation of administrative bottlenecks, not clinical AI, as the fundable wedge.
Source: Bloomberg
More that helps you.
BrainChild Bio raises $116M Series A for pediatric brain-cancer therapy
BrainChild Bio announced a $116 million Series A on September 8, 2026, backed by an undisclosed private family fund and foundation, Seattle Children's and WRF Capital. The capital…
Ridgeline raises $250M Series E at $1.425B for AI-native investment platform
Ridgeline, founded by Workday and PeopleSoft founder Dave Duffield, raised a $250M Series E on Sept 16, 2026 at a $1.425 billion valuation, with participation from Motley Fool Vent…
Stockholm's Tandem Health raises $100M Series B for an AI clinical operating system
Tandem Health raised EUR 86.49 million (about $100 million) in a Series B led by the EQT-managed Scaleup Europe Fund, announced September 14, 2026. The startup is expanding from AI…
Elucid raises $55M Series D for AI cardiovascular imaging
Boston-based Elucid announced a $55M Series D on Sept 3, 2026, led by IAG Capital Partners and Elevage. Its AI software analyzes cardiovascular imaging to detect coronary artery di…
Get briefs like this tuned to you.
In the app, Founder Briefs are personalized to your country, industry and stage, and you can save the ones that matter.
See plans →